SML4024
PZ-1922
≥95% (HPLC)
Synonym(s):
1-(3-Chlorobenzyl)-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline hydrochloride, 1-[(3-Chlorophenyl)methyl]-4-(1-piperazinyl)-1H-pyrrolo[3,2-c]quinoline hydrochloride, PZ 1922 hydrochloride, PZ1922 hydrochloride
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C22H21ClN4 · xHCl
CAS Number:
Molecular Weight:
376.88 (free base basis)
UNSPSC Code:
12352200
NACRES:
NA.21
InChI key
MFUVKDHSDIAPMH-UHFFFAOYSA-N
SMILES string
ClC1=CC(CN2C=CC3=C2C4=CC=CC=C4N=C3N5CCNCC5)=CC=C1
assay
≥95% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
Related Categories
Biochem/physiol Actions
Bioavailable triple acting, selective, high affinity 5-HT6R/5-HT3R dual antagonist and MAO-B reversible inhibitor; anti-AD agent.
PZ-1922 is a piperazinyl-pyrroloquinoline analog with favorable oral absorption and CNS penetration that simultaneously targets 5-HT6R (Ki = 17 nM), 5-HT3R (Ki = 0.45 nM), and MAO-B (pIC50 = 8.93). PZ1922 shows high selectivity over a selected panel of GPCRs, MAO-A and hERG. PZ 1922 effectively reverses cognitive impairment, prevents Aβ-induced memory decline in rodent models of Alzheimer’s disease (AD) (1.5 mg/kg/ip injection) and modulates neuroinflammatory processes.
PZ-1922 is a piperazinyl-pyrroloquinoline analog with favorable oral absorption and CNS penetration that simultaneously targets 5-HT6R (Ki = 17 nM), 5-HT3R (Ki = 0.45 nM), and MAO-B (pIC50 = 8.93). PZ1922 shows high selectivity over a selected panel of GPCRs, MAO-A and hERG. PZ 1922 effectively reverses cognitive impairment, prevents Aβ-induced memory decline in rodent models of Alzheimer’s disease (AD) (1.5 mg/kg/ip injection) and modulates neuroinflammatory processes.
Disclaimer
Hygroscopic
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Katarzyna Grychowska et al.
Journal of medicinal chemistry, 66(21), 14928-14947 (2023-10-05)
The multifactorial origin and neurochemistry of Alzheimer's disease (AD) call for the development of multitarget treatment strategies. We report a first-in-class triple acting compound that targets serotonin type 6 and 3 receptors (5-HT-Rs) and monoamine oxidase type B (MAO-B) as
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service